ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

quemliclustat

Also written as “Quemliclustat” and “AB680”.

Its studies are mostly in Pancreatic Neoplasms · Adenocarcinoma Of Esophagus · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageQuemliclustat: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 20, 20247 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arcus Biosciencesits history only61 open or runningphase 3since Sep 20, 2024Sep 18, 2018Nov 30, 2030phase 3 · NCT06608927
Gilead Sciences11 open or runningphase 2since Dec 9, 2022Dec 9, 2022Dec 2027phase 2 · NCT05676931

Also a collaborator on its studies: Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named quemliclustatINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AB680
  2. Dec 9, 2022First study: phase 2 study in Advanced Non-Small Cell Lung CancerFirst studyNCT05676931 · 400 enrolled · United States, Australia, France and more

Ahead

  1. Dec 2027Primary completion: phase 2 study in Advanced Non-Small Cell Lung CancerNCT05676931

TargetBeta

NT5E →read by rule
“A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), ”NCIt, by rule

Other programs on NT5E

ProgramCompanyFurthest phaseStudies
oleclumabAstraZenecaphase 38
uliledlimabruletj-biopharma-co-ltdphase 34

Studies

The one study Gilead Sciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05676931Advanced Non-Small Cell Lung Cancer · United States, Australia, France and more2Active, not recruitingDec 2027400

How it is read

Names in the registry

  • “Quemliclustat”, 4 entries
  • “AB680”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.